Comments
Cadila Healthcare Ltd (Zydus Cadila), on Tuesday, said it has received tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride tablets in the strengths of 50 mg/500mg and 50 mg/1000mg, respectively.
This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus, to be produced at the leading pharmaceutical group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad, the company said.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
The company shares ended the session down by 1.85 per cent at Rs 514.70 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.